AbbVie

CompanyUnited StatesFounded 2012

ROROpenAlexWikidata

AbbVie develops 57 assets, the furthest approved (ABBV-951). Mostly small molecule and antibody acting on VEGFA, ADRB1 and SNAP25; based in the United States, founded in 2012.

57
Assets
Furthest stage
Approved
961
Trials
195
Signals

Pipeline

57
  • ABBV-951

    Prodrugs supply levodopa and carbidopa, restoring brain dopamine while inhibiting peripheral levodopa breakdown.

    Approved, Small molecule, ADRB1, Parkinson's disease (Phase 3)

  • ABT-SLV187

    Enteral suspension of dopamine precursor levodopa and DOPA decarboxylase inhibitor carbidopa.

    Approved, Small molecule, advanced Parkinson disease, motor fluctuations

  • Atrasentan

    Blocks endothelin A receptor signaling involved in tumor growth and survival.

    Approved, Small molecule, EDNRA, IgA nephropathy, primary immunoglobulin a nephropathy

54 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

17

In the full profile

  • Evidence behind the mechanisms11
  • Trials1,320
  • Deals1
  • People1
  • Signals20
  • Integrity notices1
  • Similar companies6

Papers

Intelligence